Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma

Australas J Dermatol. 2024 Jun;65(4):e104-e107. doi: 10.1111/ajd.14218. Epub 2024 Feb 7.

Authors

Luca Bettolini¹, Stefano Bighetti¹, Vincenzo Maione¹, Iacopo Ghini², Diego Segala², Piergiacomo Calzavara-Pinton¹

Affiliations

¹ Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
² Pathology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

PMID: 38326991
DOI: 10.1111/ajd.14218

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone* / administration & dosage
Dexamethasone* / therapeutic use
Female
Humans
Lenalidomide* / administration & dosage
Lenalidomide* / therapeutic use
Male
Middle Aged
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy
Scleromyxedema* / drug therapy
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Lenalidomide
Dexamethasone
daratumumab
Antibodies, Monoclonal
Thalidomide